Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research

Marion T. Turnbull, Abba C. Zubair, James F. Meschia, William D. Freeman

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Significant progress has been made during the past few decades in stem cell therapy research for various diseases and injury states; however this has not been overwhelmingly translated into approved therapies, despite much public attention and the rise in unregulated ‘regenerative clinics’. In the last decade, preclinical research focusing on mesenchymal stem/stromal cell (MSC) therapy in experimental animal models of hemorrhagic stroke has gained momentum and has led to the development of a small number of human trials. Here we review the current studies focusing on MSC therapy for hemorrhagic stroke in an effort to summarize the status of preclinical and clinical research. Preliminary evidence indicates that MSCs are both safe and tolerable in patients, however future randomized controlled trials are required to translate the promising preclinical research into an effective therapy for hopeful patients.

Original languageEnglish (US)
Article number10
Journalnpj Regenerative Medicine
Issue number1
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research'. Together they form a unique fingerprint.

Cite this